Why Studying Psoriasis Comorbidities Has Been So Difficult
Researchers have long known that psoriasis comes with a higher risk of other diseases — called comorbidities. But understanding exactly how and why these conditions cluster together has been frustratingly hard. Traditional research tends to look at one disease at a time, missing the web of connections between them.
This study took a different approach.
Scientists used a mathematical framework borrowed from physics — the Ising model, which was originally designed to study how magnetic particles influence each other in a grid — to map the relationships between psoriasis and its comorbidities. By applying this model to data from a large group of patients, they built a network showing which conditions were most tightly linked to psoriasis and to each other.
The Heart-Skin Connection Moves to Center Stage
The network analysis pointed to one comorbidity above all others: atherosclerosis (the buildup of fatty plaques inside artery walls, which can lead to heart attacks and strokes) and coronary heart disease. These were identified as the core of the psoriasis comorbidity network — the most central, most connected nodes. High blood pressure, fatty liver, and pulmonary nodules were also key hubs.
Digging deeper, the researchers ran multiomics analysis — a method of looking at the body's proteins and metabolites (chemical byproducts of biological processes) simultaneously — and found a shared core mechanism: a combination of immune inflammation, oxidative stress (cellular damage caused by unstable molecules), abnormal fat metabolism, and clotting problems. One molecule called GPX3, which normally helps protect cells from oxidative damage, emerged as a particularly important hub in this network.
This does not mean treating psoriasis will automatically protect your heart — but the two conditions are more connected than previously understood.
A Drug That May Do Double Duty
Here is where the research gets practically interesting. The team also ran a prospective study (one that followed patients going forward in time) looking at what happened when psoriasis patients were treated with an IL-17A inhibitor — a class of medication already approved for moderate-to-severe psoriasis that works by blocking a specific protein (IL-17A) involved in inflammation.
After treatment, not only did patients' skin lesions improve, but early markers of atherosclerosis detected by carotid ultrasound (a sound-wave image of the arteries in the neck) also improved. Blood tests confirmed that a pro-inflammatory marker called S100A9 decreased, while anti-inflammatory molecules increased.
This suggests the drug may be quietly doing two jobs at once — calming the skin and easing vascular (blood vessel) inflammation.
What This Means if You Have Psoriasis
This research underscores why dermatologists and cardiologists increasingly work together when a patient has moderate-to-severe psoriasis. The biology linking the two systems is real, and it may be actionable.
If you are living with psoriasis — especially if you also have high blood pressure, are overweight, or smoke — it is worth having a conversation with your doctor about your overall cardiovascular risk, not just your skin management plan.
The study had meaningful limitations. The prospective intervention arm was small, and atherosclerosis was assessed by ultrasound markers rather than by clinical outcomes like heart attacks. The observational cohort data was retrospective. Larger, randomized controlled trials would be needed to confirm that IL-17A inhibitor treatment genuinely reduces heart disease risk over time.
The findings do, however, open a compelling door. If further research confirms that existing biologics (complex drugs derived from living cells) for psoriasis also protect the cardiovascular system, it could reshape treatment guidelines — moving psoriasis care from purely cosmetic-and-skin management toward a model that explicitly accounts for whole-body risk. Clinical trials designed specifically to test cardiovascular outcomes in psoriasis patients on IL-17A inhibitors are a logical and needed next step.